The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s, and potentially also help pharma to find new drug treatments.
Oxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, and why new measurements of neurodegeneration are needed.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh